This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.
Age: 18 to 60 years old;
Secondary PAP (such as secondary to blood diseases, etc.);
Patients with obvious pulmonary fibrosis, emphysema or irreversible lung function impairment;
Patients in the acute exacerbation stage;
Patients with other lung diseases (such as active pulmonary tuberculosis, bronchiectasis with purulent infection or other chronic infections; Have severe asthma, chronic bronchospasm, etc.
Jiuwu Bai
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Sponsor institution